Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Study identifies netrin-1 as novel target for atherosclerosis

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries. The research, published online by Nature Immunology on January 8, 2012, explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, accumulate in artery plaques.

10 Jan 2012

Novel target in artery plaque identified as potential therapeutic intervention

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries.

9 Jan 2012

Middle-aged adults with diabetes have time to learn how to control hypertension

A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.

9 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Cardium resolves continued listing deficiencies with NYSE Amex

Cardium Therapeutics today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC.

7 Jan 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

Repeated episodes of depression contribute to inflammation

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Abbott commences Esprit drug eluting BVS trial in peripheral artery disease

Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication.

23 Dec 2011

Reva Medical commences its first clincial trial

Reva Medical, a medical device company, has today commenced the very first clinical trial of its ReZolve™ bioresorbable coronary stent. A patient in Brazil was implanted with the device overnight, which flags an exciting chapter for Reva Medical.

21 Dec 2011

Children with SDB may have better QOL after adenotonsillectomy

Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.

20 Dec 2011

AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.

15 Dec 2011

Researchers discover how statins promote breakdown of plaque in arteries

In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries. The study was published online by the journal PLoS One on December 6, 2011.

14 Dec 2011

Abbott commences Absorb-XIENCE PRIME comparative clinical trial

Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

9 Dec 2011

Breast reconstruction after mastectomy safe for older women

Breast cancer is on the rise and 48 percent of all breast cancers occur in women older than 65, but very few of them choose to have breast reconstruction. A new study from Wake Forest Baptist Medical Center sought to determine if breast reconstruction after mastectomy is safe for older women. The answer is yes.

7 Dec 2011

MHI cardiologists use ABSORB bioresorbable vascular scaffold to treat CAD

The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.

6 Dec 2011

NASA-developed technology for treatment of hardened arteries in the heart

NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.

3 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Coronary CTA reveals different heart attack risk scenarios for men and women

Findings on coronary CT angiography (CTA), a noninvasive test to assess the coronary arteries for blockages, show different risk scenarios for men and women, according to a study presented today at the Radiological Society of North America.

30 Nov 2011

Urban legend warns about dangers of snow shoveling

Urban legend warns shoveling snow causes heart attacks, and the legend seems all too accurate, especially for male wintery excavators with a family history of premature cardiovascular disease. However, until recently this warning was based on anecdotal reports.

24 Nov 2011